Back to search

Article

In silico clinical trials of BiTE expression by oncolytic viruses reveal the impact of patient heterogeneity on dosage protocol

2026-07-06

Abstract excerpt

Immunotherapies have become a transformative therapeutic strategy for many cancer types in recent years. Bispecific T-cell engagers (BiTEs) are one promising immunotherapy that enhances cellular antitumour immunity by redirecting T cells towards cancer cells. Recent evidence suggests that BiTE efficacy can be augmented by encoding BiTEs in oncolytic measles virus vectors (MV-BiTE). Infection of cancer cells with M...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
867ffc08-8b7d-5723-98ba-937cb21fcea1
DOI
10.64898/2026.07.02.26357107
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
In silico clinical trials of BiTE expression by oncolytic viruses reveal the impact of patient heterogeneity on dosage protocolDOI 10.64898/2026.07.02.26357107
Select a neighboring publication to make it the new centre.